Therapeutic | Isecarosmab |
Target 1 | ADAMTSL5 |
Heavy Chain 1 | DVQLVESGGGVVQPGGSLRLSCAASGRTVSSYAMGWFRQAPGKEREFVAGISRSAERTYYVDSLKGRFTISRDNSKNTVYLQMNSLRPEDTALYYCAADLDPNRIFSREEYAYWGQGTLVTVSS |
Light Chain 1 | na |
100% seqID Fv 1 Structure | None |
99% seqID Fv 1 Structure | None |
95-98% seqID Fv 1 Structure | None |
Target 2 | ALB |
Heavy Chain 2 | EVQLVESGGGVVQPGNSLRLSCAASGFTFSSFGMSWVRQAPGKGLEWVSSISGSGSDTLYADSVKGRFTISRDNAKTTLYLQMNSLRPEDTALYYCTIGGSLSRSSQGTLVTVSS |
Light Chain 2 | na |
100% seqID Fv 2 Structure | None |
99% seqID Fv 2 Structure | None |
95-98% seqID Fv 2 Structure | None |
Follow these links to our prediction tools:
Format | Bispecific Single Domains (VH-VH') |
Isotype | na;na |
Highest Clinical Trial (Jan '20) | Phase-I |
Estimated Status (Jan '20) | Active |
Recorded Developmental Technology | na |
INN Year Proposed | 2019 |
INN Year Recommended | None |
Companies Involved | Merck |
Conditions Approved | na |
Conditions Active | Solid tumours |
Conditions Discontinued | na |
Notes |